Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Aytu Biopharma (AYTU) over the last 16 years, with Q4 2025 value amounting to $3.7 million.

  • Aytu Biopharma's Cash from Operations rose 2650.6% to $3.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$595000.0, marking a year-over-year decrease of 18841.01%. This contributed to the annual value of -$1.9 million for FY2025, which is 3955.33% down from last year.
  • Per Aytu Biopharma's latest filing, its Cash from Operations stood at $3.7 million for Q4 2025, which was up 2650.6% from -$618000.0 recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Cash from Operations registered a high of $19.7 million during Q1 2021, and its lowest value of -$9.1 million during Q3 2022.
  • Its 5-year average for Cash from Operations is -$1.0 million, with a median of -$989000.0 in 2024.
  • In the last 5 years, Aytu Biopharma's Cash from Operations skyrocketed by 225185.19% in 2024 and then plummeted by 244133.86% in 2025.
  • Quarter analysis of 5 years shows Aytu Biopharma's Cash from Operations stood at -$8.8 million in 2021, then soared by 72.18% to -$2.5 million in 2022, then skyrocketed by 94.49% to -$135000.0 in 2023, then surged by 2251.85% to $2.9 million in 2024, then increased by 26.51% to $3.7 million in 2025.
  • Its Cash from Operations stands at $3.7 million for Q4 2025, versus -$618000.0 for Q3 2025 and $2.8 million for Q2 2025.